Abstracts

CIO 2022-3 Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma

Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...

Siddharth A. Padia , MD;

S. Cheenu Kappadath , PhD;

Riad Salem , MD, MBA;

Bruno Sangro , MD, PhD;

Edward Kim , MD;

Daniel Sze , MD, PhD;

Marnix Lam ;

Carlo Chiesa ;

Paul Haste ;

Beau Toskich ;

Kirk Fowers ;

Joseph M. Herman ;

Thomas Leung ;

Etienne Garin ;

10/18/2022

CIO 2022-4 Preoperative Endovascular Embolization of Intracranial Meningiomas

Purpose: The purpose is to report on technical considerations involved in preoperative embolization of intracranial meningiomas. We present four cases to highlight the associated vascular...

B. Covello ;

O. Viqar ;

Waseem Wahood , MS;

B. Baigorri ;

M. Radvany ;

J. Ghostine ;

10/18/2022

CIO 2022-5 Evaluation of a Single-Institution Inferior Vena Cava Filter Retrieval Program

Purpose: Retrievable inferior vena cava (IVC) filters, if not removed, can be associated with increased mortality rates and complications. The goal of this study is to evaluate the outcom...

10/18/2022

CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option in Hepatocellular Carcinoma

Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000, which has steadily increased from 1992, when there was an incidence of 4.1 per 100,000. ...

D. Scher ;

Brennan Cronquist ;

10/18/2022

CIO 2022-7 Irreversible Electroporation versus Microwave Ablation as a Treatment Option in Hepatocellular Carcinoma

Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000 and is the most common cause of primary liver cancer worldwide. The gold-standard treatme...

Brennan Cronquist ;

D. Scher ;

10/18/2022

CIO 2022-8 Predictors of Overall Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

Purpose: To evaluate predictors of overall survival in patients with hepatocellular carcinoma (HCC) treated with lipiodol transarterial chemoembolization (cTACE).

10/18/2022

CIO 2022-9 Evaluation of Transarterial Radioembolization With Iodine-131 Lipiodol for Hepatic Metastases

Purpose: To analyze the response and survival benefits of transarterial radioembolization (TARE) with iodine-131 Lipiodol for hepatic metastases.

V. Inampudi ;

10/18/2022

CIO 2022-10 Gallium-68 Fibroblast Activation Protein Inhibitor Imaging versus FDG-PET Imaging in Hepatocellular Carcinoma

Purpose: This study aims to assess the diagnostic accuracy of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) assessment of hepatocellular carcinoma (...

V. Inampudi ;

10/18/2022

CIO 2022-11 The Role of Intraarterial Lutetium-177 DOTATATE Therapy in the Treatment of Hepatic Metastasis From Neuroendocrine Tumors

Purpose: The propensity of currently practiced intravenous lutetium-177 (177Lu) therapy to produce side effects warrants any novel techniques to reduce the side effects without compromisi...

V. Inampudi ;

10/18/2022

CIO 2022-12 Uterine Artery Embolization in the Treatment of Postpartum Uterine Hemorrhage: A Single-Center Experience in India

Purpose: To evaluate the clinical effectiveness and safety of uterine artery embolization (UAE) in the treatment of patients with primary postpartum hemorrhage (PPH), secondary PPH, and P...

S. Nimmalapudi ;

10/18/2022